Inhibrx (INBX)
(Delayed Data from NSDQ)
$34.16 USD
+0.10 (0.29%)
Updated Apr 29, 2024 04:00 PM ET
After-Market: $34.11 -0.05 (-0.15%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Income Statements
Fiscal Year end for Inhibrx, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 2 | 2 | 7 | 13 | 13 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 2 | 2 | 7 | 13 | 13 |
Selling & Adminstrative & Depr. & Amort Expenses | 221 | 131 | 84 | 80 | 57 |
Income After Depreciation & Amortization | -219 | -129 | -77 | -67 | -44 |
Non-Operating Income | 11 | 0 | 0 | 3 | -1 |
Interest Expense | 32 | 16 | 5 | 11 | 6 |
Pretax Income | -240 | -145 | -82 | -76 | -51 |
Income Taxes | 0 | 0 | 0 | 0 | 1 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | -2 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -241 | -145 | -82 | -76 | -51 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -241 | -145 | -82 | -76 | -51 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -213 | -124 | -74 | -56 | -37 |
Depreciation & Amortization (Cash Flow) | 6 | 5 | 2 | 11 | 7 |
Income After Depreciation & Amortization | -219 | -129 | -77 | -67 | -44 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 47.13 | 40.11 | 38.01 | 25.26 | NA |
Diluted EPS Before Non-Recurring Items | -5.12 | -3.62 | -2.15 | -3.01 | NA |
Diluted Net EPS (GAAP) | -5.12 | -3.62 | -2.15 | -3.01 | NA |
Fiscal Year end for Inhibrx, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 1.63 | 0.12 | 0.03 | 0.02 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 1.63 | 0.12 | 0.03 | 0.02 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 89.92 | 45.95 | 41.37 | 43.79 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -88.29 | -45.83 | -41.34 | -43.77 |
Non-Operating Income | NA | 7.02 | 2.19 | 2.20 | -0.07 |
Interest Expense | NA | 10.71 | 8.15 | 7.91 | 5.08 |
Pretax Income | NA | -91.97 | -51.79 | -47.05 | -48.92 |
Income Taxes | NA | 0.00 | 0.00 | 0.01 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | -1.63 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -93.60 | -51.79 | -47.05 | -48.92 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -93.60 | -51.79 | -47.05 | -48.92 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 54.04 | 47.15 | 43.64 | 43.58 |
Diluted EPS Before Non-Recurring Items | NA | -1.73 | -1.10 | -1.08 | -1.12 |
Diluted Net EPS (GAAP) | NA | -1.82 | -1.10 | -1.08 | -1.12 |